APA (7th ed.) Citation

DR, S., DL, S., DM, W., SF, J., PJ, W., KC, S., . . . JD, H. (2019). A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. The oncologist, 24(12), e1409. https://doi.org/10.1634/theoncologist.2018-0518

Chicago Style (17th ed.) Citation

DR, Spigel, et al. "A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or Without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial." The Oncologist 24, no. 12 (2019): e1409. https://doi.org/10.1634/theoncologist.2018-0518.

MLA (9th ed.) Citation

DR, Spigel, et al. "A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or Without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial." The Oncologist, vol. 24, no. 12, 2019, p. e1409, https://doi.org/10.1634/theoncologist.2018-0518.